Dermsquared

While the rest of the country is scraping ice off the windshield this January, a new wave in dermatology is rolling into Miami, and it's built around your clinical practice.

Total Impact Miami is a new kind of meeting, built around your goals instead of a fixed schedule. Tell us where you want to grow before you arrive and your schedule gets shaped around it. On site, you learn hands-on with a cohort of peers who share your focus, across clinical, aesthetic, and practice impact. You go home with an action plan you can put to work Monday morning.

January 15 to 17, 2027. JW Marriott Turnberry Resort & Spa, Aventura, Florida.

Learn more here: https://bit.ly/4wdjTGB

Patients with atopic dermatitis who aren't clearing on a biologic don't always have treatment-resistant AD. In some cases, allergic contact dermatitis may be contributing to persistent disease.​

James Q. Del Rosso, DO, and Walter Liszewski, MD, break down when patch testing belongs in the AD workup on Derms and Conditions.​

In this episode, they cover:​
-Why allergic contact dermatitis gets missed, and its overlap with AD and irritant contact dermatitis​
-Why patients receiving biologic therapy may still have residual disease, and how patch testing can help clarify the cause​
-The "paraben paradox" and why barrier integrity matters when evaluating allergic contact dermatitis​
​
Listen here: https://bit.ly/4wbOGUq

​

Recognition and management of cutaneous lupus erythematosus (CLE) has moved forward. Here's what that looks like in practice.

In this on-demand activity, Saakshi Khattri, MD, and Lauren Graham, MD, PhD, explore the diagnostic features that separate CLE subtypes, differential considerations across skin colors, and where newer targeted options fit based on subtype, disease activity, and prior treatment.

Earn up to 0.5 𝘈𝘔𝘈 𝘗𝘙𝘈 𝘊𝘢𝘵𝘦𝘨𝘰𝘳𝘺 1 𝘊𝘳𝘦𝘥𝘪𝘵(𝘴)™.

Start the activity, Seeing CLE Clearly: Optimizing Recognition and Enhancing Management of Cutaneous Lupus Erythematosus, at: https://bit.ly/4aLi5Mv

This activity is supported by an educational grant from Biogen.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared®. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.5 𝘈𝘔𝘈 𝘗𝘙𝘈 𝘊𝘢𝘵𝘦𝘨𝘰𝘳𝘺 1 𝘊𝘳𝘦𝘥𝘪𝘵(𝘴)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

What's driving the next wave of hidradenitis suppurativa (HS) therapies?

Andrea T. Murina, MD, and Harrison Nguyen, MD, MPH, MBA, walk through the mechanisms and trial data in Under the Skin: Targeting the Mechanisms Underlying Hidradenitis Suppurativa, a new on-demand CME activity.

In this activity, you’ll:
-Distinguish emerging HS therapies by mechanism of action
-Review the latest clinical evidence for new and emerging HS treatments

Earn up to 0.5 𝘈𝘔𝘈 𝘗𝘙𝘈 𝘊𝘢𝘵𝘦𝘨𝘰𝘳𝘺 1 𝘊𝘳𝘦𝘥𝘪𝘵(𝘴)™.

Start the activity at https://bit.ly/4aLi5Mv

This activity is supported by an educational grant from Incyte.



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared®. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.5 𝘈𝘔𝘈 𝘗𝘙𝘈 𝘊𝘢𝘵𝘦𝘨𝘰𝘳𝘺 1 𝘊𝘳𝘦𝘥𝘪𝘵(𝘴)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.